AIFM2 and non-small cell lung carcinoma: In particular, in Kelch-like ECH-associated protein 1 (KEAP1) mutant non-small cell lung cancer (NSCLC), the overexpression of FSP1 induced cross-resistance to GPX4 inhibitors [131].